AltruBio
Redwood City
CA
United States
26 articles about AltruBio
-
AltruBio Announces Enrollment of First Patient in Phase 2 Clinical Program of ALTB-268 for the Treatment of Ulcerative Colitis
12/7/2023
AltruBio Inc. today announced the first patient enrolled for the Phase 2a clinical study of the company’s subcutaneously administered immune checkpoint enhancer (ICE), ALTB-268 in ulcerative colitis (UC).
-
AltruBio Announces FDA Clearance of IND Application for Immune Checkpoint Enhancer ALTB-268 to initiate a Phase 2 Clinical Trial for the Treatment of Ulcerative ColitisGlobal multi-arm Phase 2 clinical trial expected to launch in 2024
9/26/2023
AltruBio Inc. announced clearance of its Investigational New Drug application from the U.S. Food and Drug Administration to initiate a Phase 2 clinical study of the company’s subcutaneously administered immune checkpoint enhancer, ALTB-268 in ulcerative colitis.
-
AltruBio Announces Positive Topline Data from Phase 1 Trial of Immune Checkpoint Enhancer ALTB-268 for the Treatment of Ulcerative Colitis
8/1/2023
AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of immunological diseases with high unmet medical needs, today announced positive topline data from its Phase 1 trial evaluating the company’s subcutaneously administered immune checkpoint enhancer (ICE), ALTB-268 in healthy volunteers.
-
AltruBio to Present at the Federation of Clinical Immunology Societies (FOCIS) 2023 Annual Meeting
6/15/2023
AltruBio Inc. announced that the company will be giving an oral presentation on its immune checkpoint enhancer, ALTB-268, as well as feature a poster on ICE ALTB-168 at the 2023 Federation of Clinical Immunology Societies Annual Meeting, which is being held June 20-23, 2023 in Boston, Massachusetts.
-
AltruBio to Present at the 2023 BIO International Convention
5/31/2023
AltruBio Inc. announced that President and Chief Executive Officer Judy Chou, Ph.D., will present an in-person corporate overview at the 2023 BIO International Convention taking place June 5-8, 2023, in Boston, MA.
-
AltruBio Announces Poster Presentation at Digestive Disease Week Conference 2023
5/8/2023
AltruBio Inc. today announced that David T. Rubin, M.D., Professor of Medicine and Pathology at the University of Chicago and AltruBio Scientific Advisory Board member, will share a poster presentation on immune checkpoint enhancer (ICE), ALTB-168, during Digestive Disease Week®, taking place at McCormick Place in Chicago, IL, from May 6-9, 2023.
-
AltruBio Announces Panels and Presentations at Three March Healthcare Conferences
3/9/2023
AltruBio Inc. announced that it will take part in three healthcare conferences in March, including Biologics Manufacturing Asia, Longwood Healthcare Leaders CEO Conference and Festival of Biologics World Antibody Congress USA.
-
AltruBio Announces First Patient Dosed in Phase 1 Trial of Next-Generation Immune Checkpoint Enhancer ALTB-268 for the Treatment of Ulcerative Colitis
1/23/2023
AltruBio Inc. (“AltruBio” or “the Company”) today announced that it has dosed the first patient in a Phase 1 study evaluating ALTB-268, its next-generation PSGL-1 antibody agonist serving as an immune checkpoint enhancer (ICE), in healthy volunteers.
-
AltruBio Announces Poster Presentation on Immune Checkpoint Enhancer, ALTB-168 at Crohn’s & Colitis Congress 2023
1/19/2023
AltruBio Inc. (“AltruBio” or “the Company”) today announced that David T. Rubin, M.D., Professor of Medicine at the University of Chicago and AltruBio Scientific Advisory Board member, will share a poster presentation on first-generation immune checkpoint enhancer (ICE), ALTB-168 (neihulizumab), at the Crohn’s & Colitis Congress 2023, to be held in Denver, Colorado on January 19-21, 2023.
-
AltruBio to Present at Biotech Showcase™ 2023
1/5/2023
AltruBio Inc. announced that its President and Chief Executive Officer Judy Chou, Ph.D. will present a corporate overview at Biotech Showcase™ 2023 taking place in San Francisco, California from January 9-11, 2023.
-
AltruBio Presents New Positive Data from its Completed Phase 1b Study Evaluating ALTB-168 in Patients with Steroid-Refractory or Treatment-Refractory Acute Graft-Versus-Host-Disease at the 64th ASH Annual Meeting 2022
12/10/2022
AltruBio Inc. announced the presentation of new data from its completed Phase 1b clinical trial evaluating ALTB-168 in patients with steroid-refractory or treatment-refractory acute graft-versus-host-disease at the 64th American Society of Hematology Annual Meeting, taking place December 10-13, 2022 in New Orleans, La.
-
AltruBio Hosting Research & Development Update on Immune Checkpoint Enhancer Platform for T Cell Mediated Immunological Diseases
12/8/2022
AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of immunological diseases with high unmet medical needs, today announced that the company will host a research and development update on its immune checkpoint enhancer platform for T cell mediated immunological diseases on Thursday, December 15, 2022 at 12 p.m. ET.
-
AltruBio Announces FDA Clearance of IND Application for ALTB-268, a Next-Generation Immune Checkpoint Enhancer for the Treatment of Ulcerative Colitis
12/6/2022
AltruBio Inc. today announced clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical study of ALTB-268 in healthy volunteers..
-
According to a BIO report, less than a third of executive team members are women. BioSpace spoke with three influential women in biopharma to get their advice on breaking the executive barrier.
-
AltruBio to Present at Stifel 2022 Healthcare Conference
11/8/2022
AltruBio Inc. announced that AltruBio President and Chief Executive Officer Judy Chou, Ph.D., and Chief Financial Officer Jeroen Grasman will present a corporate overview at the Stifel 2022 Healthcare Conference taking place November 15-16, 2022 in New York, NY.
-
AltruBio to Present New Phase 1b Data Evaluating Neihulizumab (ALTB-168) in Patients with Steroid-Refractory or Treatment-Refractory Acute Graft-Versus-Host-Disease at the 64th ASH Annual Meeting 2022
11/3/2022
AltruBio Inc. announced the poster presentation of new data from its Phase 1b clinical trial evaluating neihulizumab in patients with steroid-refractory or treatment-refractory acute graft-versus-host-disease at the 64th American Society of Hematology Annual Meeting, taking place December 10-13, 2022 in New Orleans, La.
-
AltruBio President and CEO Judy Chou Appointed to the Governing Board of California’s Stem Cell & Gene Therapy Agency
11/1/2022
AltruBio Inc. announced that AltruBio President and CEO Judy Chou, Ph.D., has been appointed to the Independent Citizens’ Oversight Committee, the governing Board of the California Institute for Regenerative Medicine.
-
AltruBio President and CEO Judy Chou to Participate at the Longwood Healthcare Leaders Fall Webconference
9/16/2022
AltruBio Inc. announced that AltruBio President and CEO Dr. Judy Chou will speak on “The Next Wave of Targeted Therapies” at the Longwood Healthcare Leaders Fall Webconference on Wednesday, September 21, 2022.
-
AltruBio to Present at the 2022 BIO International Convention
6/6/2022
AltruBio Inc. announced that president and chief executive officer Judy Chou, Ph.D., will present an in-person corporate overview at the 2022 BIO International Convention taking place June 13-16, 2022 in San Diego, Calif.
-
AltruBio Announces Completion of Enrollment in Phase 1 Clinical Study of Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
5/12/2022
AltruBio Inc. today announced that enrollment has been completed for the Phase 1 clinical study of neihulizumab (ALTB-168) in patients with steroid-refractory acute graft-versus-host disease (SR-aGVHD).